don't ask me where that stupid red smiley face came from...no...

First 118 Last

Share
Profile

Follow
turps

8,604 Posts.

83

05/07/18

14:01

Post #: 34161657
Share

Originally posted by turps ↑

just a reminder...

Phosphagenics' oxymorphone patch storms phase I

By Dylan Bushell-Embling
Thursday, 24 October, 2013

Phosphagenics (ASXOH) has completed the world’s first in-human trial of transdermal delivery of oxymorphone, with a phase I trial of its TPM/oxymorphone patch.
The patch was shown to deliver therapeutic plasma concentrations of oxymorphone in all 12 healthy volunteer subjects.
The participants each received repeated applications of a three-day sustained release TPM/oxymorphone pain patch, mimicking a real-life pain medication regime.
All 12 subjects demonstrated oxymorphone plasma concentrations well above the threshold therapeutic concentrations produced by the oral long-acting or extended-release dosage form of oxymorphone, Opana ER, within the first application period.
Phosphagenics said the results show that the maximum plasma concentration in subjects can be as high as that produced by the highest-strength Opana ER tablet, 40 mg. But TPM/oxymorphone only contains about 25% of the oxymorphone used in high dosage strengths of the pill form, reducing the potential for abuse.
“The importance of the success of this trial cannot be overstated. While we were confident going into the trial, the magnitude of the oxymorphone concentration in plasma surpassed our expectations,” Phosphagenics Chief Scientific Officer Dr Paul Gavin said.
“Not only can the patch deliver therapeutic amounts of oxymorphone, the results suggest that the patch can compete with the therapeutic value of the higher dosage strengths of the oral product and surpass them with respect to bioavailability.”
Phosphagenics CEO Harry Rosen said on the strength of the results that the company will shift its emphasis for a planned phase II trial from proving the product’s analgesic capabilities to defining the dosing regimes to be used with the product.
“The questions as to whether our opioid patch technology works have been categorically answered by these results. The task is now to work with our pain experts and regulatory consultants to progress the project through the next phases of the clinical trial and regulatory processes, as well as licensing discussions.”
The company aims to commence the phase II trial in mid-2014. Phosphagenics projects that peak sales of a successfully commercialised TPM/oxycodone could reach as high as $1.4 billion a year.
Phosphagenics also plans to commence a phase II trial of another opioid pain patch, TPM/oxycodone, in 2014.
Phosphagenics (ASXOH) shares were trading 42.86% higher at $0.15 as of around 2.30 pm on Thursday.

Related Articles

we've got the patches ready....ph2 is on the cards

Expand

don't ask me where that stupid red smiley face came from...no idea!

POH Price at posting: 1.6¢ Sentiment: Buy Disclosure: Held
1 Upvote

0 Great analysis

Reply

Top Stories

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

TMG

Trigg shares up 16% on Wild Cattle Creek antimony acquisition

Week 39 Wrap: What HotCopper’s watching; China’s new stimmy moves boost metals; Oz CPI drop

HAS

Hastings progressing Yangibana to production with lower costs

There are more pages in this discussion • 1 more message in this thread...

First 118 Last

Add AVE (ASX) to my watchlist

(20min delay)
Last 0.2¢		Change 0.000(0.00%)		Mkt cap ! $6.338M

Open	High	Low	Value	Volume
0.2¢	0.2¢	0.2¢	$500	250K

Buyers (Bids)

No.	Vol.	Price($)
34	45759211	0.2¢

Sellers (Offers)

Price($)	Vol.	No.
0.3¢	45970683	27

View Market Depth

No.	Vol.	Price($)
34	46009211	0.002
17	23466742	0.001
0	0	0.000
0	0	0.000
0	0	0.000

Price($)	Vol.	No.
0.003	45970683	27
0.004	34898435	19
0.005	15900219	9
0.006	17380067	10
0.007	5572471	5

Last trade - 13.36pm 30/09/2024 (20 minute delay)

AVE (ASX) Chart

don't ask me where that stupid red smiley face came from...no...

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Trigg shares up 16% on Wild Cattle Creek antimony acquisition

Week 39 Wrap: What HotCopper’s watching; China’s new stimmy moves boost metals; Oz CPI drop

Hastings progressing Yangibana to production with lower costs

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

don't ask me where that stupid red smiley face came from...no...

Top Stories

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Trigg shares up 16% on Wild Cattle Creek antimony acquisition

Week 39 Wrap: What HotCopper’s watching; China’s new stimmy moves boost metals; Oz CPI drop

Hastings progressing Yangibana to production with lower costs

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News